Noonan syndrome type I with PTPN11 3 bp deletion: Structure–function implications
- 1 November 2004
- journal article
- research article
- Published by Wiley in Proteins-Structure Function and Bioinformatics
- Vol. 58 (1), 7-13
- https://doi.org/10.1002/prot.20296
Abstract
Noonan syndrome was recently reported to be caused by mutations in the PTPN11 gene in 40% of the cases. This gene encodes the nonreceptor‐type protein tyrosine phosphatase SHP‐2 and has been shown to be self down‐regulated with the concurrency of two SH2 domains. Insertion of a specific loop (D′EF) from N‐terminal SH2 domain into the SHP‐2 active‐site is responsible for the reversible inhibition of the phosphatase activity. Here we report the first in frame trinucleotide deletion resulting in the removal of Aspartate 61 (D61del), a key residue of the N‐terminal SH2 D′EF loop. Energetic‐based structural analysis and electrostatic calculations carried out on the wild‐type and mutant proteins predict lower stability of the D′EF loop for the D61del variant as compared to the wild type indicating better access to the active site and most likely an enzyme activated for longer extent. Similar computations were performed on the previously functionally characterized gain‐of‐function D61Y mutant and similar behaviors were observed. The simulation data for the D61del and D61Y mutants suggest that both variants could yield more catalytic cycles than the wild‐type molecule in the same timespan because of the opening of the active site. It also supports the notion that D61 plays a major role for proper down‐regulation of the protein tyrosine phosphatase activity of SHP‐2. Proteins 2005.This publication has 41 references indexed in Scilit:
- Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndromeEuropean Journal of Human Genetics, 2003
- PTPN11 Mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13Human Mutation, 2002
- PTPN11(Protein-Tyrosine Phosphatase, Nonreceptor-Type 11) Mutations in Seven Japanese Patients with Noonan SyndromeJournal of Clinical Endocrinology & Metabolism, 2002
- PTPN11 Mutations in Noonan Syndrome: Molecular Spectrum, Genotype-Phenotype Correlation, and Phenotypic HeterogeneityAmerican Journal of Human Genetics, 2002
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndromeNature Genetics, 2001
- A role for the SHP-2 tyrosine phosphatase in nerve growth-induced PC12 cell differentiation.Molecular Biology of the Cell, 1997
- Multiple Requirements for SHPTP2 in Epidermal Growth Factor-Mediated Cell Cycle ProgressionMolecular and Cellular Biology, 1996
- The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early xenopus developmentCell, 1995
- The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp.Proceedings of the National Academy of Sciences, 1993
- Hypertelorism With Turner PhenotypeAmerican Journal of Diseases of Children, 1968